Tocilizumab and liver injury in patients with COVID-19
Tocilizumab and liver injury in patients with COVID-19
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Current mortality rate in patients with COVID-19 disease is about 2%, whereas 5% of patients require admission to the intensive care unit. It is assumed that interleukin (IL)-6 may be involved in the pathogenesis of severe COVID-19 infections; therefore, in the absence of a specific antiviral therapy, some authors have suggested that tocilizumab –...
Alternative Titles
Full title
Tocilizumab and liver injury in patients with COVID-19
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4e90bcd874ce485e8a7f0a103120dee0
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4e90bcd874ce485e8a7f0a103120dee0
Other Identifiers
ISSN
1756-2848,1756-283X
E-ISSN
1756-2848
DOI
10.1177/1756284820959183
